Education
About Us
Working with TipRanks
Follow Us
Spero Therapeutics Inc (SPRO)
NASDAQ:SPRO
SPRO Stock Chart & Stats
$2.17
-$0.03(-2.91%)
At close: 4:00 PM EST
$2.17
-$0.03(-2.91%)
Day’s Range― - ―
52-Week Range$0.51 - $3.22
Previous CloseN/A
Volume61.58K
Average Volume (3M)311.11K
Market Cap
$122.26M
Enterprise Value$76.99M
Total Cash (Recent Filing)$48.62M
Total Debt (Recent Filing)$3.35M
Price to Earnings (P/E)―
Beta1.76
Next Earnings
Mar 26, 2026EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding56,339,294
10 Day Avg. Volume277,656
30 Day Avg. Volume311,106
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.21
Price to Sales (P/S)1.16
P/FCF Ratio-2.37
Enterprise Value/Market Cap0.63
Enterprise Value/Revenue2.15
Enterprise Value/Gross Profit-1.06
Enterprise Value/Ebitda-1.71
Forecast
1Y Price Target
$4.00Price Target Upside84.33% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-0.64
Revenue Forecast (FY)$800.00K
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessAnalyst points out that the Phase 3 trial for tebipenem met its primary endpoint early and was stopped for efficacy, strengthening the case for a robust regulatory submission and improved commercial prospects.
Financial Runway And Cost ControlAnalyst observes that reduced research spending after trial completion, together with cash reserves expected to support operations into 2028, lowers near-term financing risk and enhances financial stability.
Partnership MilestonesAnalyst highlights that the licensing agreement with GSK includes multiple milestone payments and tiered royalties that could deliver significant non-dilutive revenue if regulatory and commercial triggers are achieved.
Bears Say
Milestone Payment ReductionAnalyst warns that early trial termination led to a prorated milestone payment materially below initial expectations, reducing anticipated near-term cash inflows from the GSK deal.
Operating LossesAnalyst notes a reported net loss that highlights ongoing operating deficits and raises the possibility of additional financing needs if anticipated partner payments or royalties are delayed.
Spero Therapeutics News
SPRO FAQ
What was Spero Therapeutics Inc’s price range in the past 12 months?
Spero Therapeutics Inc lowest stock price was $0.51 and its highest was $3.22 in the past 12 months.
What is Spero Therapeutics Inc’s market cap?
Spero Therapeutics Inc’s market cap is $122.26M.
When is Spero Therapeutics Inc’s upcoming earnings report date?
Spero Therapeutics Inc’s upcoming earnings report date is Mar 26, 2026 which is in 24 days.
How were Spero Therapeutics Inc’s earnings last quarter?
Spero Therapeutics Inc released its earnings results on Nov 13, 2025. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.25 by $0.12.
Is Spero Therapeutics Inc overvalued?
According to Wall Street analysts Spero Therapeutics Inc’s price is currently Undervalued.
Does Spero Therapeutics Inc pay dividends?
Spero Therapeutics Inc pays a Quarterly dividend of $0.015 which represents an annual dividend yield of N/A. See more information on Spero Therapeutics Inc dividends here
What is Spero Therapeutics Inc’s EPS estimate?
Spero Therapeutics Inc’s EPS estimate is -0.2.
How many shares outstanding does Spero Therapeutics Inc have?
Spero Therapeutics Inc has 56,339,294 shares outstanding.
What happened to Spero Therapeutics Inc’s price movement after its last earnings report?
Spero Therapeutics Inc reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.25. Following the earnings report the stock price went down -1.23%.
Which hedge fund is a major shareholder of Spero Therapeutics Inc?
Currently, no hedge funds are holding shares in SPRO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Spero Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$4.00 (84.33% Upside)
$4.00 (84.33% Upside)
Blogger Sentiment
Bullish
SPRO Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 22.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $393.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 4.8%
Last 30 Days ▼ 4.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
178.56%
12-Months-Change
Fundamentals
Return on Equity
-95.29%
Trailing 12-Months
Asset Growth
-59.92%
Trailing 12-Months
Company Description
Spero Therapeutics Inc
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
SPRO Stock 12 Month Forecast
Average Price Target
$4.00
▲(84.33% Upside)
Technical Analysis
Milestone Pharmaceuticals
―
Korro Bio
―
Connect Biopharma Holdings
―
Tenaya Therapeutics
―
Contineum Therapeutics, Inc. Class A
―
Ownership Overview
5.32% Insiders
4.10% Mutual Funds
22.96% Other Institutional Investors
64.42% Public Companies and
Individual Investors